Gene info: ID 783

Gene: CACNB2

GENE ID: 783

Synonyms: CACNLB2|CAVB2|MYSB

Description: calcium voltage-gated channel auxiliary subunit beta 2

Gene type: protein-coding

Location: 10p12.33-p12.31

dbXrefs: Ensembl:ENSG00000165995 MIM:600003 Vega:OTTHUMG00000017764 UniprotKB:Q08289

RefSeq: NG_016195.1

Retrived from: SNP Mapped

SNPs: 2 ANCO-SNPs

Phenotype: ND

# Publications: 0

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 7.891e-1 (AD) 3.819e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs12240995	chr10:18348303 (GRCh38.p7)	A>C	nicotine dependence	SNV(Single Nucleotide Variation)
rs1277769	chr10:18210865 (GRCh38.p7)	C>A	nicotine dependence	SNV(Single Nucleotide Variation)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg12289251	chr10:18689471	CACNB2		4.200e-13	Smoking	27651444
cg24128066	chr10:18689503	CACNB2		1.200e-10	Smoking	27651444
cg00177243	chr10:18434068	CACNB2		7.800e-10	Smoking	27651444
cg22858500	chr10:18629006	CACNB2		2.200e-9	Smoking	27651444
cg14357089	chr10:18550033	CACNB2		9.100e-8	Smoking	27651444
cg00476617	chr10:18492374	CACNB2		9.700e-8	Smoking	27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
NCEH1	0.954
FBXO34	0.953
GABRB3	0.951
DAPK1	0.945
NOL4	0.944
CNKSR2	0.943
CDK20	0.942
AMIGO1	0.941
RBFOX2	0.94
GRIA2	0.939

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
RAI14	-0.543
SGMS2	-0.517
MYL3	-0.511
TFPI2	-0.506
FZD10	-0.502
HEY2	-0.501
CTNNA3	-0.5
CSAG1	-0.497
TGFB3	-0.487
SH2D1A	-0.477

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB11093	Calcium Citrate	Small Molecule	813-94-5	Approved	Transporter
DB11348	Calcium Phosphate	Small Molecule	10103-46-5	Approved	Transporter
DB00270	Isradipine	Small Molecule	75695-93-1	Approved\|Investigational	Target
DB00381	Amlodipine	Small Molecule	88150-42-9	Approved	Target
DB00393	Nimodipine	Small Molecule	66085-59-4	Approved\|Investigational	Target
DB00401	Nisoldipine	Small Molecule	63675-72-9	Approved	Target
DB00622	Nicardipine	Small Molecule	55985-32-5	Approved\|Investigational	Target
DB00653	Magnesium sulfate	Small Molecule	7487-88-9	Approved\|Investigational	Target
DB00661	Verapamil	Small Molecule	52-53-9	Approved	Target
DB01023	Felodipine	Small Molecule	72509-76-3	Approved\|Investigational	Target
DB01054	Nitrendipine	Small Molecule	39562-70-4	Approved\|Investigational	Target
DB01115	Nifedipine	Small Molecule	21829-25-4	Approved	Target
DB01388	Mibefradil	Small Molecule	116644-53-2	Investigational\|Withdrawn	Target
DB04855	Dronedarone	Small Molecule	141626-36-0	Approved	Target
DB06712	Nilvadipine	Small Molecule	75530-68-6	Approved\|Investigational	Target
DB00421	Spironolactone	Small Molecule	52-01-7	Approved	Target
DB09089	Trimebutine	Small Molecule	39133-31-8	Approved	Target
DB09231	Benidipine	Small Molecule	105979-17-7	Approved\|Investigational	Target
DB09232	Cilnidipine	Small Molecule	132203-70-4	Approved\|Investigational	Target
DB09236	Lacidipine	Small Molecule	103890-78-4	Approved\|Investigational	Target
DB09238	Manidipine	Small Molecule	89226-50-6	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of CACNB2 mRNA"	19114083
C023035	3,4,5,3',4'-pentachlorobiphenyl	"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CACNB2 mRNA"	23196670
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of CACNB2 mRNA	29067470
D000082	Acetaminophen	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	25607892
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of CACNB2 mRNA	16483693
D000726	Androgen Antagonists	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	25607892
C006632	arsenic trioxide	arsenic trioxide results in increased expression of CACNB2 mRNA	20458559
C015001	arsenite	arsenite results in increased methylation of CACNB2 promoter	23974009
D001280	Atrazine	Atrazine results in decreased expression of CACNB2 mRNA	25929836
C547126	AZM551248	AZM551248 results in decreased expression of CACNB2 mRNA	22323515
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of CACNB2 mRNA	22228805
D004958	Estradiol	Estradiol results in decreased expression of CACNB2 mRNA	21185374
C006780	bisphenol A	bisphenol A affects the methylation of CACNB2 promoter	27415467
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	25607892
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA	25607892
C006780	bisphenol A	bisphenol A results in decreased expression of CACNB2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of CACNB2 gene	28505145
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	25607892
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA	25607892
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of CACNB2 mRNA	17484886
D020245	p-Chloromercuribenzoic Acid	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in decreased expression of CACNB2 mRNA	26272509
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CACNB2 gene	20938992
D003010	Clorgyline	Clorgyline results in increased expression of CACNB2 mRNA	19691856
D016572	Cyclosporine	Cyclosporine results in decreased expression of CACNB2 mRNA	20106945
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in increased expression of CACNB2 mRNA	23914054
C058705	diethyl malate	diethyl malate affects the expression of CACNB2 mRNA	24814887
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	25607892
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA	25607892
C074283	estradiol 3-benzoate	estradiol 3-benzoate results in increased methylation of CACNB2 promoter	27415467
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of CACNB2 mRNA	15212814
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CACNB2 gene	20938992
D019833	Genistein	Genistein results in increased expression of CACNB2 mRNA	24967385
C002385	linsidomine	linsidomine results in increased oxidation of CACNB2 protein	28086193
C042720	mercuric bromide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CACNB2 gene	20938992
D008731	Methoxychlor	Methoxychlor results in increased methylation of CACNB2 gene	23303685
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of CACNB2 mRNA	28001369
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of CACNB2 mRNA	26924002
C523799	MRK 003	CACNB2 results in increased susceptibility to MRK 003	19903844
D009151	Mustard Gas	Mustard Gas affects the expression of CACNB2 mRNA	15651846
D009532	Nickel	Nickel results in decreased expression of CACNB2 mRNA	25583101
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	25607892
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA	25607892
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
C496932	panobinostat	panobinostat results in decreased expression of CACNB2 mRNA	26272509
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in decreased expression of CACNB2 mRNA	19162173
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of CACNB2 mRNA	26272509
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of CACNB2 mRNA	23608068
C009277	sodium arsenate	sodium arsenate results in increased expression of CACNB2 mRNA	21795629
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CACNB2 mRNA	20106945
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased methylation of CACNB2 gene	26756918
D014241	Trichloroethylene	Trichloroethylene results in increased methylation of CACNB2 gene	27618143
D014415	Tunicamycin	Tunicamycin results in increased expression of CACNB2 mRNA	17127020
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of CACNB2 gene	25560391
D014750	Vincristine	Vincristine results in increased expression of CACNB2 mRNA	23649840

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005245	voltage-gated calcium channel activity	-	IDA	1309651
GO:0005262	calcium channel activity	-	NAS	9594024
GO:0005515	protein binding	-	IPI	17525370
GO:0008331	high voltage-gated calcium channel activity	-	IBA	21873635
GO:0008331	high voltage-gated calcium channel activity	contributes_to	IDA	1309651
GO:0051015	actin filament binding	-	ISS	25533460
GO:0086007	voltage-gated calcium channel activity involved in cardiac muscle cell action potential	contributes_to	IMP	17224476
GO:0086056	voltage-gated calcium channel activity involved in AV node cell action potential	contributes_to	IMP	17224476

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0007268	chemical synaptic transmission	-	IBA	21873635
GO:0007528	neuromuscular junction development	-	IBA	21873635
GO:0007528	neuromuscular junction development	-	TAS	8494331
GO:0007601	visual perception	-	IEA	-
GO:0051928	positive regulation of calcium ion transport	-	IDA	1309651
GO:0070509	calcium ion import	-	IDA	1309651
GO:0070588	calcium ion transmembrane transport	-	IEA	-
GO:0072659	protein localization to plasma membrane	-	ISS	25533460
GO:0086045	membrane depolarization during AV node cell action potential	-	IMP	17224476
GO:0086091	regulation of heart rate by cardiac conduction	-	IMP	17224476
GO:0098912	membrane depolarization during atrial cardiac muscle cell action potential	-	IMP	17224476
GO:1901385	regulation of voltage-gated calcium channel activity	-	IBA	21873635
GO:1901843	positive regulation of high voltage-gated calcium channel activity	-	ISS	25533460
GO:1904879	positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	-	ISS	25533460

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	NAS	9594024
GO:0005891	voltage-gated calcium channel complex	-	IBA	21873635
GO:0005891	voltage-gated calcium channel complex	-	IDA	17224476
GO:1990454	L-type voltage-gated calcium channel complex	-	IDA	1309651

KEGG ID	KEGG Term
hsa04010	MAPK signaling pathway
hsa04260	Cardiac muscle contraction
hsa05410	Hypertrophic cardiomyopathy (HCM)
hsa05412	Arrhythmogenic right ventricular cardiomyopathy (ARVC)
hsa05414	Dilated cardiomyopathy

Reactome ID	Reactome Term	Evidence
R-HSA-112308	Presynaptic depolarization and calcium channel opening	TAS
R-HSA-112315	Transmission across Chemical Synapses	TAS
R-HSA-112316	Neuronal System	TAS
R-HSA-1266738	Developmental Biology	IEA
R-HSA-1430728	Metabolism	TAS
R-HSA-1430728	Metabolism	IEA
R-HSA-163685	Integration of energy metabolism	TAS
R-HSA-163685	Integration of energy metabolism	IEA
R-HSA-375165	NCAM signaling for neurite out-growth	IEA
R-HSA-397014	Muscle contraction	TAS
R-HSA-400042	Adrenaline,noradrenaline inhibits insulin secretion	IEA
R-HSA-419037	NCAM1 interactions	IEA
R-HSA-422356	Regulation of insulin secretion	TAS
R-HSA-422356	Regulation of insulin secretion	IEA
R-HSA-422475	Axon guidance	IEA
R-HSA-5576891	Cardiac conduction	TAS
R-HSA-5576892	Phase 0 - rapid depolarisation	TAS
R-HSA-5576893	Phase 2 - plateau phase	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal